journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/30224273/survival-by-histologic-subtype-of-malignant-pleural-mesothelioma-and-the-impact-of-surgical-resection-on-overall-survival
#1
Vivek Verma, Christopher A Ahern, Christopher G Berlind, William D Lindsay, Jacob Shabason, Sonam Sharma, Melissa J Culligan, Surbhi Grover, Joseph S Friedberg, Charles B Simone
INTRODUCTION: For the 3 histologic subtypes of malignant pleural mesothelioma (MPM)-epithelioid, sarcomatoid, and biphasic-the magnitude of benefit with surgical management remains underdefined. MATERIALS AND METHODS: The National Cancer Data Base was queried for newly diagnosed nonmetastatic MPM with known histology. Patients in each histologic group were dichotomized into those receiving gross macroscopic resection versus lack thereof/no surgery. Kaplan-Meier analysis evaluated overall survival (OS) between cohorts; multivariable Cox proportional hazards modeling assessed factors associated with OS...
August 29, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30228011/ceritinib-alone-for-crizotinib-naive-versus-crizotinib-pretreated-for-management-of-anaplastic-lymphoma-kinase-rearrangement-non-small-cell-lung-cancer-a-systematic-review
#2
REVIEW
Xuewei Zhao, Zhangying Feng, Guanqi Wang, Haiying Pang, Mingxia Wang
Ceritinib shows a promising efficacy in patients with anaplastic lymphoma kinase (ALK)-rearrangement non-small-cell lung cancer (NSCLC). The present systematic review determined the whole body and intracranial effectiveness and safety of ceritinib in crizotinib-naive versus crizotinib-pretreated regimens in ALK-rearrangement NSCLC. A comprehensive search of databases, including PubMed, EMBASE, Ovid, Web of Science, and COCHRANE, was performed to identify clinical trials in English-language journals. We estimated the pooled progression-free survival (PFS) and overall response rate (ORR) for ceritinib in whole body and intracranial responses to find differences between crizotinib-naive and crizotinib-pretreated regimens...
August 23, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197265/phase-iii-randomized-trial-of-palonosetron-and-dexamethasone-with-or-without-aprepitant-to-prevent-nausea-and-vomiting-induced-by-full-dose-single-day-cisplatin-based-chemotherapy-in-lung-cancer
#3
Fang Wu, Xiaoping Lin, Zhanghuan Yang, Ziyi Sun, Fanxu Zeng, Jianfu Heng, Jingjing Qu, Liang Zeng, Nong Yang, Yongchang Zhang
INTRODUCTION: This study aimed to determine the efficacy and safety of aprepitant, palonosetron, and dexamethasone to prevent chemotherapy-induced nausea and vomiting in patients with locally advanced or metastatic lung cancer receiving full-dose single-day cisplatin-based combination chemotherapy. MATERIALS AND METHODS: Patients diagnosed with locally advanced or metastatic lung cancer who received full dose single-day cisplatin-based chemotherapy were randomized (1:1) to aprepitant plus palonosetron and dexamethasone, or placebo plus palonosetron and dexamethasone...
August 23, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30219240/radiation-dose-and-fractionation-for-limited-stage-small-cell-lung-cancer-survey-of-us-radiation-oncologists-on-practice-patterns
#4
Matthew J Farrell, Jehan B Yahya, Catherine Degnin, Yiyi Chen, John M Holland, Mark A Henderson, Jerry J Jaboin, Matthew M Harkenrider, Charles R Thomas, Timur Mitin
BACKGROUND: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. MATERIALS AND METHODS: We surveyed US radiation oncologists using an institutional review board-approved questionnaire...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30217639/kras-specific-amino-acid-substitutions-are-associated-with-different-responses-to-chemotherapy-in-advanced-non-small-cell-lung-cancer
#5
Stéphane Renaud, Francesco Guerrera, Joseph Seitlinger, Jérémie Reeb, Anne-Claire Voegeli, Michèle Legrain, Bertrand Mennecier, Nicola Santelmo, Pierre-Emmanuel Falcoz, Elisabeth Quoix, Marie-Pierre Chenard, Noëlle Weingertner, Michèle Beau-Faller, Gilbert Massard
BACKGROUND: Emerging data highlight different clinical behaviors according to KRAS amino acid substitutions (AASs) in patients with non-small-cell lung cancer (NSCLC). We aimed to evaluate whether different KRAS AASs were associated with different responses to chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed data from 1190 patients with KRAS mutations who underwent first-line platinum-based chemotherapy for stage IV NSCLC. The response to different chemotherapy regimens was evaluated using the Response Evaluation Criteria In Solid Tumors criteria (v 1...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30206043/sex-dependent-staging-in-non-small-cell-lung-cancer-analysis-of-the-effect-of-sex-differences-in-the-eighth-edition-of-the-tumor-node-metastases-staging-system
#6
Zoe Wainer, Gavin M Wright, Karla Gough, Marissa G Daniels, Prudence A Russell, Peter Choong, Matthew Conron, David Ball, Benjamin Solomon
INTRODUCTION: Non-small-cell lung cancer (NSCLC) has disproportionately negative outcomes in men compared with women. The importance of the relationship between sex and tumor, node, metastases (TNM) staging system remains unknown. The objective of this study was to investigate the effect of sex on NSCLC survival for each stage in the eighth edition of the TNM staging system in NSCLC. PATIENTS AND METHODS: Two cohorts treated surgically with curative intent between 2000 and 2010 were analyzed...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30206042/rapid-and-highly-sensitive-detection-of-therapeutically-relevant-oncogenic-driver-mutations-in-ebus-tbna-specimens-from-patients-with-lung-adenocarcinoma
#7
Filiz Oezkan, Thomas Herold, Kaid Darwiche, Wilfried E E Eberhardt, Karl Worm, Daniel C Christoph, Marcel Wiesweg, Lutz Freitag, Kurt-Werner Schmid, Dirk Theegarten, Thomas Hager, Michael J Koenig, Kai He, Christian Taube, Martin Schuler, Frank Breitenbuecher
BACKGROUND: First-line afatinib treatment prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring exon 19 deletion of epidermal growth factor receptor (EGFRdelEx19) mutations. In contrast, Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations are negative predictors for benefit from EGFR-targeting agents. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is well-established for lung cancer diagnosis and staging...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30201223/prophylactic-cranial-irradiation-versus-surveillance-physician-bias-and-patient-centered-decision-making
#8
Skyler B Johnson, Roy H Decker
An original work in this month's issue of Clinical Lung Cancer highlights the role of physician bias in the decision to recommend prophylactic cranial irradiation (PCI) to patients with small-cell lung cancer, and presents a patient decision aid to facilitate discussion. After decades of clinical trials, we've learned that PCI can significantly decrease the risk of brain metastases and possibly improve survival. However, PCI is also associated with negative impacts on cognition and quality of life. At present, there is no consensus on how to balance these risks and benefits...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197264/osimertinib-with-ramucirumab-in-egfr-mutated-t790m-positive-patients-with-progression-during-egfr-tki-therapy-phase-ib-study
#9
Hiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Toshio Shimokawa, Nobuyuki Yamamoto
BACKGROUND: Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism of resistance among patients with progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. A third-generation EGFR-TKI, osimertinib, demonstrated durable efficacy with mild adverse events in a phase III trial and is considered a novel standard regimen. The tolerability of osimertinib monotherapy has allowed for the development of a more efficacious combination regimen. Preclinical and clinical study data have suggested that vascular endothelial growth factor inhibition can enhance EGFR-TKI activity with tolerable toxicity...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197263/twice-daily-thoracic-radiotherapy-for-limited-stage-small-cell-lung-cancer-does-not-increase-the-incidence-of-acute-severe-esophagitis
#10
Ryoko Suzuki, Xiong Wei, Pamela K Allen, James W Welsh, James D Cox, Ritsuko Komaki, Steven H Lin
PURPOSE: Acute esophagitis is common after thoracic radiation therapy (TRT) given with chemotherapy for limited-stage small-cell lung cancer (LS SCLC). Although twice-daily TRT to 45 Gy in 30 fractions is considered standard, some clinicians are reluctant to use this schedule because of its perceived impracticality and risk of severe esophagitis. We reviewed a single-institution experience with severe (grade ≥ 3) esophagitis after TRT with chemotherapy for LS SCLC. PATIENTS AND METHODS: A total of 504 patients were identified as having received TRT (≥45 Gy) with platinum-containing chemotherapy for LS SCLC at MD Anderson Cancer Center in 1987 through 2012...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197262/pd-1-and-pd-l1-protein-expression-predict-survival-in-completely-resected-lung-adenocarcinoma
#11
Bojan Zaric, Luka Brcic, Anna Buder, Anita Brandstetter, Jorun O Buresch, Stefan Traint, Tomi Kovacevic, Vladimir Stojsic, Branislav Perin, Robert Pirker, Martin Filipits
BACKGROUND: We assessed the prognostic value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in patients with completely resected lung adenocarcinoma. PATIENTS AND METHODS: PD-1 and PD-L1 expression was determined using immunohistochemistry in formalin-fixed paraffin-embedded surgical specimens and correlated with the clinicopathologic features and survival of 161 patients with lung adenocarcinoma. RESULTS: PD-1 expression on immune cells was observed in 71 of 159 evaluable tumor samples (45%) and was not significantly associated with the clinicopathologic features...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197261/first-line-chemotherapy-responsiveness-and-patterns-of-metastatic-spread-identify-clinical-syndromes-present-within-advanced-kras-mutant-non-small-cell-lung-cancer-with-different-prognostic-significance
#12
Wade T Iams, Hui Yu, Yu Shyr, Tejas Patil, Leora Horn, Caroline McCoach, Karen Kelly, Robert C Doebele, D Ross Camidge
BACKGROUND: Unsuccessful KRAS-specific treatment approaches in non-small-cell lung cancer (NSCLC) might reflect underlying disease heterogeneity. We sought to define clinical "syndromes" within advanced KRAS mutant NSCLC to improve future clinical trials and create a clinical framework for future molecular development. PATIENTS AND METHODS: To test a series of a priori hypotheses regarding KRAS-mutant NSCLC clinical syndromes, we conducted a multi-institutional retrospective medical record review...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197260/bronchoscopic-manifestations-of-airway-toxicity-after-radiotherapy
#13
Juliët E van Hoorn, Max Dahele, Johannes M A Daniels
No abstract text is available yet for this article.
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30197259/incidence-risk-factors-and-effect-on-survival-of-immune-related-adverse-events-in-patients-with-non-small-cell-lung-cancer
#14
Dwight H Owen, Lai Wei, Erin M Bertino, Thomas Edd, Miguel A Villalona-Calero, Kai He, Peter G Shields, David P Carbone, Gregory A Otterson
BACKGROUND: The risk factors for immune-related adverse events (irAEs) remain undefined. Recently, a correlation between irAEs and clinical benefit was suggested. We examined the risk factors for irAEs and their effect on survival in patients with non-small-cell lung cancer (NSCLC) who had received immunotherapy. PATIENTS AND METHODS: We performed a retrospective review of patients with NSCLC treated with single-agent immunotherapy at our institution. irAEs were determined by treating physician diagnosis...
August 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30172698/study-protocol-phase-ib-trial-of-nivolumab-combined-with-metformin-for-refractory-recurrent-solid-tumors
#15
Toshio Kubo, Takashi Ninomiya, Katsuyuki Hotta, Toshiyuki Kozuki, Shinichi Toyooka, Hiroyuki Okada, Toshiyoshi Fujiwara, Heiichiro Udono, Katsuyuki Kiura
Although immune checkpoint inhibitors have shown significant survival benefits in the treatment of several cancers, optimal outcomes have been limited to certain subsets of patients. In a previous study, we found that the addition of metformin to nivolumab, an anti-programmed cell death protein 1 (PD-1) antibody, yielded substantial tumor regression in mouse models. Further analysis revealed that the number of tumor-infiltrating CD8 T cells had increased markedly. Based on this result, we have launched an investigator-initiated open-label phase-Ib clinical trial...
August 9, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30206044/docetaxel-plus-ramucirumab-with-primary-prophylactic-pegylated-granulocyte-colony-stimulating-factor-support-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-a-multicenter-prospective-single-arm-phase-ii-trial-dragon-study-wjog9416l
#16
Akito Hata, Nobuyuki Katakami, Mototsugu Shimokawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
We exhibit our ongoing multicenter, prospective, single-arm, phase II trial of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) support for chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (NSCLC) (University Hospital Medical Information Network database: UMIN000030598). Docetaxel monotherapy is the Japanese standard of care for chemotherapy-naive elderly patients with advanced NSCLC. Docetaxel plus ramucirumab showed superior survival benefit over docetaxel monotherapy in the second-line setting for NSCLC...
August 7, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30087028/phase-1b-study-of-momelotinib-combined-with-trametinib-in-metastatic-kirsten-rat-sarcoma-viral-oncogene-homolog-mutated-non-small-cell-lung-cancer-after-platinum-based-chemotherapy-treatment-failure
#17
David A Barbie, Alexander Spira, Karen Kelly, Rita Humeniuk, Jun Kawashima, Shengchun Kong, Marianna Koczywas
INTRODUCTION: Specific treatment options are lacking for Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) despite treatment advances in other mutation-driven subgroups. PATIENTS AND METHODS: In this study we evaluated the multitargeted Janus kinase/TANK-binding kinase 1 (TBK1) inhibitor momelotinib combined with the mitogen/extracellular signal-related kinase (MEK)1/MEK2 inhibitor trametinib in patients with platinum-treated, refractory, metastatic, KRAS-mutated NSCLC...
August 4, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30143457/pemetrexed-vitamin-b12-and-thoracic-tumors-the-times-they-are-a-changin
#18
Paolo Bironzo, Giorgio Vittorio Scagliotti
The administration of pemetrexed requires routine supplementation with vitamin B12 and folate, even if blood concentrations are normal, in order to mitigate its hematologic toxicity. Emerging data suggest that such premedication can be initiated less than 1 week before starting chemotherapy. The current available data on later administration of vitamin B12 in patients with thoracic tumors are placed into a general context, and the possible role of such strategy in the era of immunooncology is discussed.
August 2, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30131257/comparison-of-single-and-five-fraction-regimens-of-stereotactic-body-radiation-therapy-for-peripheral-early-stage-non-small-cell-lung-cancer-a-two-institution-propensity-matched-analysis
#19
Michael A Cummings, Sung Jun Ma, Gregory Hermann, Lucas Serra, Yusef Syed, Harish K Malhotra, Yuhchyau Chen, Michael T Milano, Jorge A Gomez-Suescun, Deepinder P Singh, Anurag K Singh
PURPOSE: To evaluate differences in local control (LC), disease-specific (DC), and overall survival (OS) of patients with early-stage non-small-cell lung cancer (NSCLC) treated with single- (SF) versus 5-fraction (FF) stereotactic body radiation therapy (SBRT) at 2 institutions. PATIENTS AND METHODS: Peripheral early-stage NSCLC cases treated with a median dose of 30 Gy in SF or a median dose of 50 Gy in FF were included per institutional practice. Kaplan-Meier and Cox models were used to assess survival...
July 30, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30122430/dynamic-changes-and-drug-induced-selection-of-resistant-clones-in-a-patient-with-egfr-mutated-adenocarcinoma-that-acquired-t790m-mutation-and-transformed-to-small-cell-lung-cancer
#20
Yuki Iijima, Yosuke Hirotsu, Hitoshi Mochizuki, Kenji Amemiya, Toshio Oyama, Yoshinori Uchida, Yoichi Kobayashi, Toshiharu Tsutsui, Yumiko Kakizaki, Yoshihiro Miyashita, Masao Omata
No abstract text is available yet for this article.
July 26, 2018: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"